Delayed Onset of Autoimmune Hemolytic Anemia Complicating Cladribine Therapy for Waldenström Macroglobulinemia

References

• Dimopoulos M., Alexanian R. Waldenström's macroglobulinemia. Blood 1994; 83(6)1452–1459
   PubMed Web of Science ®Google Scholar
• MacKenzie M.R., Fudenberg H.H. Macroglobulinemia–An analysis of 40 patients. Blood 1972; 39: 874–889
   PubMed Web of Science ®Google Scholar
• Kyle R.A., Garton J.P. The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clinic Proceedings 1987; 62: 719–731
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., O'Brien S., Kantarjian H., Pierce S., Delasalle K., Barlogie B., Alexanian R., Keating M.J. Fludarabine therapy in Waldenström's macroglobulinemia. American Journal of Medicine 1993; 95: 49–52
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., Kantarjian H.M., Estey E.H., O'Brien S., Delasalle K., Keating M.J., Freireich E.J., Alexanian R. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Annals of Internal Medicine 1993; 118: 195–198
   PubMed Web of Science ®Google Scholar
• Bergmann L., Feuchel K. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Annals of Oncology 1993; 4: 371–375
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R.H., Kosty M., Beutler E., Piro L.D. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. Journal of Clinical Oncology 1995; 13: 570–574
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L.D. Complete remissions in hairy cell leukemia with 2-chlorodeoxyaadenosine after failure with 2′-deoxycoformycin. Annals of Internal Medicine 1993; 119: 278–283
   PubMed Web of Science ®Google Scholar
• Saven A., Burian C., Koziol J.A., Piro L.D. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 1998; 92: 1918–1926
   PubMed Web of Science ®Google Scholar
• Tallman M.S., Hakimian D., Variakojis D., Koslow D., Sisney G.A., Rademaker A.W., Rose E., Kaul K. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 9: 2203–2209
   Google Scholar
• Byrd J.C., Hertles A.A., Weiss R.B. Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia. Annals of Oncology 1995; 6: 300–301
   PubMed Web of Science ®Google Scholar
• Dhodapkar M., Jacobsen J., Gertz M., Crowley J., Shurafa M., Salmon S., Kyle R., Barlogie B. Phase II intergroup trial of fludarabine (FAMP) in Waldenström's macroglobulinemia (WM): Results of Southwest Oncology Group trial (SWOG 9003) in 220 patients. Blood 1997; 90(Suppl. 1)2571
   Google Scholar
• Kantarjian H.M., Alexanian R., Koller C., Kurzrock R., Keating M.J. Fludarabine therapy in macroglob-ulinemic lymhomas. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Zinzani P.L., Gherlinzoni F., Bendandi M., Zaccaria A., Aitini E., Salvucci M., Tura S. Fludarabine treatment in resistant Waldenström macroglobulinemia. European Journal of Haematology 1995; 54: 120–123
   PubMed Web of Science ®Google Scholar
• Liu E., Burian C., Miller W.E., Saven A. Bolus cladribine in the treatment of Waldenström macroglobulinemia. British Journal of Haematology 1998; 103: 690–695
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., Kantarjian H., Weber D., O'Brien S., Estey E., Delasalle K., Rose E., Cabanillas F., Keating M., Alexanian R. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine. Journal of Clinical Oncology 1994; 12: 2694–2698
   PubMed Web of Science ®Google Scholar
• Cheson B.D. Infections and immunosuppressive complications of purine analog therapy. Journal of Clinical Oncology 1995; 13: 2431–2448
   PubMed Web of Science ®Google Scholar
• Saven A. The Scripps Clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia. Seminars in Hematology 1996; 33: 28–33
   PubMed Web of Science ®Google Scholar
• Myint H., Copplestone J.A., Orchard J. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukemia. British Journal of Haematology 1995; 91: 341–344
   PubMed Web of Science ®Google Scholar
• DiRaimondo F., Giustolisi R., Cacciola E. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leukemia and Lymphoma 1993; 11: 63–68
   Web of Science ®Google Scholar
• Weiss R.B., Freeman J., Kweder S.L., Diehl L.F., Byrd J.C. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 1998; 16: 1885–1889
   PubMed Web of Science ®Google Scholar
• Piro L.D., Carrera C.J., Beutler E., Carson D.A. 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72: 1069–1073
   PubMed Web of Science ®Google Scholar
• Robak T., Blasinska-Morawiec M., Krykowski E., Hellman A., Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia treated with 2-chlorodeoxyadenosine (cladribine). European Journal of Haematology 1997; 58: 109–113
   PubMed Web of Science ®Google Scholar
• Fleischman R.A., Croy D. Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia (Letter). American Journal of Hematology 1995; 48: 293
   PubMed Web of Science ®Google Scholar
• Pritsch O., Maloum K., Dighiero G. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Seminars In Oncology 1998; 25(1)34–41
   PubMed Web of Science ®Google Scholar
• Byrd J.C., Weiss R.B., Kweder S.L. Fludarabine therapy for lymphoid malignancies is associated with hemolytic anemia. Proceedings of the American Society of Clinical Oncology 1994; 13: 304
   Google Scholar
• Bastion Y., Coiffier B., Dumonet C. Severe autoimmune hemolytic anemia in two patients treated with fludarabine for chronic lymphocytic leukemia. Annals of Oncology 1992; 3: 171–172
   PubMed Web of Science ®Google Scholar
• Kroft S.H., Tallman M.S., Shaw J.M., Thangavelo M., Peterson L.C. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (2-CdA). Leukemia 1997; 1(1)170
   Web of Science ®Google Scholar
• Rozman C., Montserrat E. Chronic lymphocytic leukemia. New England Journal of Medicine 1995; 333: 1052–1057
   PubMed Web of Science ®Google Scholar
• Anaissie E.J., Kontoyiannis D.P., O'Brien S., Kantarjian H., Robertson L., Lerner S., Keating M.J. Infections in patients with chronic lymphocyte leukemia treated with fludarabine. Annals of Internal Medicine 1998; 129(7)559–566
   PubMed Web of Science ®Google Scholar
• Tosti S., Caruso R., Adamo F. Severe autoimmune hemolytic anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. Annals of Hematology 1992; 65: 238–239
   PubMed Web of Science ®Google Scholar
• Kay N.E., Howe R.B., Douglas S.D. Effect of therapy on T-cell subpopulations in patients with chronic lymphocytic leukemia. Leukemia Research 1982; 6: 345–348
   PubMed Web of Science ®Google Scholar
• Beutler E., Koziol J.A., McMillan R. Marrow suppression produced by repeated doses of cladribine. Acta Haematologica 1994; 91: 10–15
   PubMed Web of Science ®Google Scholar
• Beutler E., Piro L.D., Saven A., Kay A.C., McMillan R., Longmire R., Carrera C.J., Morin P., Carson D.A. 2-Chlorodeoxyadenosine (2-CdA): A potent chemotherapeutic and immunosuppressive nucleotide. Leukemia and Lymphoma 1991; 5: 1–8
   PubMed Web of Science ®Google Scholar